Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (61-70 of 159) with videos related to

Pageof 16
Sort By:
Seminars in Oncology|August 1, 1995
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancerE K Rowinsky, W A Flood, S E Sartorius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cardiac disturbances during the administration of taxolE K Rowinsky, W P McGuire, T Guarnieri, et al.
Anti-Cancer Drugs|May 18, 1999
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assayM Hidalgo, E Izbicka, C Cerna, et al.
Blood|March 15, 1997
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cellsS H Kaufmann, P A Svingen, S D Gore, et al.
Journal of the National Cancer Institute|December 19, 1990
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitorsE K Rowinsky, R C Donehower, J L Spivak, et al.
Cancer Research|November 1, 1987
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological studyE K Rowinsky, D S Ettinger, W P McGuire, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropeniaW J Slichenmyer, R C Donehower, T L Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancerE K Rowinsky, D S Ettinger, L B Grochow, et al.
Journal of the National Cancer Institute|July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activityE K Rowinsky, D A Noe, D W Orr, et al.
Blood|March 15, 1990
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitroR J Jones, S J Sharkis, C B Miller, et al.
Pageof 16

Showing results (61-70 of 159) with videos related to

Sort By:
Pageof 16
Seminars in Oncology|August 1, 1995
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancerE K Rowinsky, W A Flood, S E Sartorius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cardiac disturbances during the administration of taxolE K Rowinsky, W P McGuire, T Guarnieri, et al.
Anti-Cancer Drugs|May 18, 1999
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assayM Hidalgo, E Izbicka, C Cerna, et al.
Blood|March 15, 1997
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cellsS H Kaufmann, P A Svingen, S D Gore, et al.
Journal of the National Cancer Institute|December 19, 1990
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitorsE K Rowinsky, R C Donehower, J L Spivak, et al.
Cancer Research|November 1, 1987
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological studyE K Rowinsky, D S Ettinger, W P McGuire, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropeniaW J Slichenmyer, R C Donehower, T L Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancerE K Rowinsky, D S Ettinger, L B Grochow, et al.
Journal of the National Cancer Institute|July 6, 1988
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activityE K Rowinsky, D A Noe, D W Orr, et al.
Blood|March 15, 1990
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitroR J Jones, S J Sharkis, C B Miller, et al.
Pageof 16